Dividends, Diverse Product Pipelines, Acquisitions, Financial Results - Research Report on Quest Diagnostics, PerkinElmer,

   Dividends, Diverse Product Pipelines, Acquisitions, Financial Results -
Research Report on Quest Diagnostics, PerkinElmer, Waters, Alere, and TearLab

PR Newswire

NEW YORK, September 3, 2013

NEW YORK, September 3, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Quest
Diagnostics Inc. (NYSE: DGX), PerkinElmer Inc. (NYSE: PKI), Waters Corp.
(NYSE: WAT), Alere Inc. (NYSE: ALR), and TearLab Corporation (NASDAQ: TEAR).
Today's readers may access these reports free of charge - including full price
targets, industry analysis and analyst ratings - via the links below.

Quest Diagnostics Inc. Research Report

On August 20, 2013, Quest Diagnostics Inc.'s (Quest Diagnostics) Board of
Directors has approved a quarterly cash dividend of $0.30 per share. The
Company informed that the dividend is payable on October 16, 2013 to
shareholders of record of the Company's common stock on October 1, 2013. The
Full Research Report on Quest Diagnostics Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.analystscorner.com/r/full_research_report/05ba_DGX]

--

PerkinElmer Inc. Research Report

On August 29, 2013, PerkinElmer Inc. (PerkinElmer) announced the launch of the
first commercially available screening test for Severe Combined
Immunodeficiency (SCID) in Europe and the Middle East. According to the
Company, the EnLite™ Neonatal TREC System - the new screening test widens the
newborn screening portfolio of commercially available tests. Bobby Gaspar,
M.D, Ph.D., Professor of Pediatrics and Immunology at London's Great Ormond
Street Hospital for Children and the UCL Institute of Child Health said, "With
the availability of PerkinElmer's new test for screening SCID, clinicians will
be able to diagnose patients more quickly and precisely, improving quality of
life and transplant outcome for newborns affected by this highly debilitating
and potentially fatal condition." The Full Research Report on PerkinElmer Inc.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/2016_PKI]

--

Waters Corp. Research Report

On August 7, 2013, Waters Corp. (Waters) announced that it has acquired
Nonlinear Dynamics Ltd., a world leader in proteomics and metabolomics
analysis software based in Newcastle upon Tyne, U.K. Waters informed that
with complex biological samples and more sensitive analytical techniques,
managing experimental data continues to be a challenge and by acquiring
Nonlinear Dynamics, the Company expects to address this challenge. Dr. Rohit
Khanna, Vice President of Informatics and Worldwide Marketing for the Waters
Division said, "The opportunity to combine Nonlinear Dynamics informatics
expertise with Waters worldwide leadership in chromatography and mass
spectrometry will continue to create significant benefits for omics-focused
scientists and laboratories, Proteomics, metabolomics, and lipidomics hold
vast potential for understanding the mechanisms of diseases, the development
of innovative therapeutics, and discovering biomarkers for translational
research." The Full Research Report on Waters Corp. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.analystscorner.com/r/full_research_report/2fff_WAT]

--

Alere Inc. Research Report

On August 8, 2013, Alere Inc. reported that its subsidiary, Alere Analytics
(Alere) has announced the launch of its Electronic Laboratory Reporting (ELR)
Solution to aid hospitals in submitting reportable lab results to State
Departments of Health. As stated by the Company, the ELR solution is
delivered on the Alere Analytics platform using a cloud-based, SaaS
environment and it captures all codes associated with diseases, conditions,
lab tests and demographic data by leveraging industry messaging standards, and
then delivers this information to the appropriate state authority. Mansoor
Khan, Sc.D., CEO of Alere commented, "In addition to continuing to work with
State Departments of Health, we are now pleased to directly offer hospital
labs in all states our proven ELR technology as a low-cost, simple and
effective way to satisfy Meaningful Use Stage 2, as well as provide a
comprehensive solution to improve efficiency, patient safety, and outcomes
while maximizing reimbursements." The Full Research Report on Alere Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/5da1_ALR]

--

TearLab Corporation Research Report

On August 13, 2013, TearLab Corp. (TearLab) reported its Q2 2013 consolidated
financial results with net revenues of $3.5 million, up 392.3% YoY. Loss from
operations stood $5.3 million, in Q2 2013, compared to $2.5 million in Q2
2012. The Company's net loss for the quarter totaled $12 million or $0.41 per
diluted share, compared to a net loss of $2 million or $0.10 per diluted share
in Q2 2012. Elias Vamvakas, TearLab's CEO said, "We were very pleased with the
strong level of support from both new and existing investors in our recent
financing, This has provided us with necessary resources to continue expanding
our sales organization, building widespread awareness and clinical use of the
TearLab Osmolarity test, while creating an unprecedented partnership within
the eye care community." The Full Research Report on TearLab Corporation -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/58d3_TEAR]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

http://www.analystscorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)